HiCisco (002653.SZ) received the IND application for the innovative drug HSK46575 tablets for new indications

Zhitong Finance App News, HiCisco (002653.SZ) issued an announcement. The company's subsidiary, Liaoning Hisco Pharmaceutical Co., Ltd., recently received the “Acceptance Notice” issued by the State Drug Administration, involving the drug “HSK46575.” Clinical trial applications for this product in combination with olapalil tablets or docetaxel and prednisone tablets for the treatment of prostate cancer were accepted.

HSK46575 tablets are an oral, potent and highly selective small molecule inhibitor independently developed by the company and intended for the treatment of prostate cancer. Pre-clinical research results show that this product has clear targets, accurate curative effects, and good safety. It is a small molecule drug with great potential for development. It has a high benefit/risk ratio for clinical application, and has broad clinical application prospects. It is expected to become an effective treatment for prostate cancer and solve the current problem of lack of clinical medication. According to the requirements for chemical drug registration classification in the notice issued by the State Drug Administration on the “Registration Classification of Chemical Drugs and Application Data Requirements” (No. 44 of 2020), this product is a chemical drug category 1.